Lung Cancer
Volume 57 , Pages S24-S29 , August 2007

Optimising survival in malignant mesothelioma

  • Paul Baas

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +31 (0) 20 512 2958; fax: +31 (0) 25 572 2572

References 

  1. De Kleck NH , Musk AW . Epidemiology of mesothelioma . In:  Robinson BWS ,  Chahinian AP editor. Mesothelioma . London: Martin Dunitz; 2002;p. 339–350
  2. Ismail-Khan R , Robinson LA , Williams CC , Garrett CR , Bepler G , Simon GR . Malignant pleural mesothelioma: a comprehensive review . Cancer Control . 2006;13:255–263
  3. Curran D , Sahmoud T , Therasse P , et al.   Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience . J Clin Oncol . 1998;16:145–152
  4. Coppola D , Szabo M , Boulware D , et al.   Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies . Clin Cancer Res . 2004;10:184–190
  5. Scherpereel A , Grigoriu B , Conti M , et al.   Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma . Am J Respir Crit Care Med . 2006;175:1155–1160
  6. Pass HI , Lott D , Lonardo F , et al.   Asbestos exposure, pleural mesothelioma, and serum osteopontin levels . N Engl J Med . 2005;353:1564–1573
  7. Butchart EG , Ashcroft T , Barnsley WC , et al.   Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients . Thorax . 1976;31:15–24
  8. Mattson K . Natural history and clinical staging of malignant mesothelioma . Eur J Respir Dis . 1982;63(Suppl 124):87
  9. Chahinian AP . Therapeutic modalities in malignant pleural mesothelioma . In:  Chretien J ,  Hirsch A editor. Disease of the pleura . New York: Masson; 1983;p. 224
  10. Spiessl B , Beahrs OH , Hermanek P , et al.   International Union against Cancer. TNM Atlas: Illustrated Guide to the TNM/PTNM Classification of Malignant Tumours . 3rd ed.. Berlin, New York: Springer-Verlag; 1992; 2nd revision.
  11. Boutin C , Rey F , Gouvernet J , et al.   Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging . Cancer . 1993;72:394–404
  12. Sugarbaker DJ , Strauss GM , Lynch TJ , et al.   Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma . J Clin Oncol . 1993;11:1172–1178
  13. Rusch VW . A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group . Chest . 1995;108:1122–1128
  14. Herndon JE , Green MR , Chahinian AP , et al.   Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B . Chest . 1998;113:723–731
  15. Edwards JG , Abrams KR , Leverment JN , et al.   Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems . Thorax . 2000;55:731–735
  16. Potti A , Mukherjee S , Petersen R , et al.   A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer . N Engl J Med . 2006;355:570–580
  17. Baas P , Schouwink H , Zoetmulder FA . Malignant pleural mesothelioma . Ann Oncol . 1998;9:139–149
  18. Ong ST , Vogelzang NJ . Chemotherapy in malignant pleural mesothelioma. A review . J Clin Oncol . 1996;14:1007–1017
  19. Albert AS , Falkson G , Goedhals L , et al.   Malignant pleural mesothelioma: a disease unaffected by current therapeutic manoeuvres . J Clin Oncol . 1998;6:527–535
  20. Berghmans T , Paesmans M , Lalami Y , et al.   Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis . Lung Cancer . 2002;38:111–121
  21. Vogelzang NJ , Rusthoven JJ , Symanowski J , et al.   Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma . J Clin Oncol . 2003;21:2636–2644
  22. Vogelzang NJ . Standard therapy for the treatment of malignant pleural mesothelioma . Lung Cancer . 2005;50(Suppl 1):S23–S24
  23. van Meerbeeck JP , Gaafar R , Manegold C , et al.   Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada . J Clin Oncol . 2005;23:6881–6889
  24. Ceresoli GL , Zucali PA , Favaretto AG , et al.   Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma . J Clin Oncol . 2006;24:1443–1448
  25. O'Brien ME , Watkins D , Ryan C , et al.   A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial . Ann Oncol . 2006;17:270–275
  26. Jassem J , Ramlau R , Santoro A , et al.   A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM) . Ann Oncol . 2006;(Suppl 9):ix214
  27. Takahashi JA , Fukumoto M , Igarashi K , et al.   Correlation of basic fibroblast growth factor expression levels with degree of malignancy and vascularity in human gliomas . J Neurosurg . 1992;76:792–798
  28. Zagzag D , Miller DC , Sato Y , et al.   Immunohistochemical localization of basic fibroblast growth factor in astrocytomas . Cancer Res . 1990;50:7393–7398

PII: S0169-5002(07)70424-5

doi: 10.1016/S0169-5002(07)70424-5

Lung Cancer
Volume 57 , Pages S24-S29 , August 2007

Article Tools